D‐Peptide‐Based Drug Discovery Aided by Chemical Protein Synthesis

Le Zhao,Wuyuan Lu

DOI: https://doi.org/10.1002/ijch.201100085

2011-01-01

Abstract:Despite a sharp increase in the expenditures for drug research and development (R&D) in the past decade, the declining trend in the number of new drugs approved annually by the US Food and Drug Administration continues. This growing disparity between R&D investment and new drug approvals results in part from the deficiency in promising therapeutic targets and leads to a stagnation exacerbated by the lack of advanced drug discovery tools for harvesting the “high‐hanging fruits” such as inhibitors of protein–protein interactions (PPIs). Small peptide inhibitors of PPIs can be of high affinity and specificity, promising an important class of therapeutic agents that target PPIs involved in a great variety of biological processes. However, susceptibility to proteolytic degradation in vivo still remains a major hurdle that limits their therapeutic potential. This limitation can be overcome by mirror‐image phage display, a technique that allows, through phage‐expressed peptide library screening against the D ‐enantiomer of a target protein, for the identification of proteolysis‐resistant D ‐peptide inhibitors of PPIs. Recent advances in total protein synthesis via native chemical ligation have significantly expanded the scope of molecular targets for mirror‐image phage display. This concise review focuses on the latest development in the combined use of mirror‐image phage display and native chemical ligation for D ‐peptide based anticancer drug discovery.